Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is an unblinded, randomized clinical study comparing the efficacy of DNA damaging chemotherapy using carboplatin, to standard of care therapy for patients who have metastatic castrate resistant prostate cancer. This trial will use olaparib or carboplatin as initial therapy with crossover to the alternate or second-line drug after first progression for patients with tumors containing BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D, or RAD54L inactivating mutations. Participants are randomized (1:1) and receive either carboplatin (AUC 5, IV) every 21 days, first or olaparib taken orally (300 mg), twice daily in 28 day cycles, until intolerance, complete response, or progression by Prostate Cancer Working Group 3 (PCWG3) criteria. Participants then crossover from the first-line therapy to the second-line therapy with the opposite study medication and receive treatment to intolerance or progression (whichever is first). Enrolled participants will be allowed to crossover to second line therapy if they continue to meet initial eligibility criteria, and at least three weeks have elapsed since last administration of either carboplatin or olaparib. Throughout the study, safety and tolerability will be assessed. Progression will be evaluated with bone scan, CT of the abdomen/pelvis, or MRI and PSA as per PCWG3 criteria.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony rak prostaty (z wyjątkiem czystej odmiany małokomórkowej)
- •Ciągła terapia hormonalna (leki hamujące hormony lub operacja usunięcia jąder)
- •Zaawansowany rak prostaty oporny na standardowe leczenie hormonalne
- •Wcześniejsze leczenie lekami abiraterone, enzalutamide, apalutamide lub darolutamide
- •Potwierdzenie mutacji genów RAD51B, RAD51C, RAD51D lub RAD54L (lub innych specjalnych mutacji)
- •Ogólny stan zdrowia pozwalający na chemioterapię
- •Prawidłowe funkcje wątroby, nerek i szpiku kostnego
- •Podpisana zgoda na udział w badaniu
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 17, 2026
- Sex
- Male only
Therapies / drugs in trial
Locations (18)
VA Greater Los Angeles Healthcare System, West Los Angeles, CA
West Los Angeles, United States
Rocky Mountain Regional VA Medical Center, Aurora, CO
Aurora, United States
Washington DC VA Medical Center, Washington, DC
Washington D.C., United States
Bay Pines VA Healthcare System, Pay Pines, FL
Bay Pines, United States
Orlando VA Medical Center, Orlando, FL
Orlando, United States
Atlanta VA Medical and Rehab Center, Decatur, GA
Decatur, United States
Boise VA Medical Center, Boise, ID
Boise, United States
Jesse Brown VA Medical Center, Chicago, IL
Chicago, United States
VA Ann Arbor Healthcare System, Ann Arbor, MI
Ann Arbor, United States
Minneapolis VA Health Care System, Minneapolis, MN
Minneapolis, United States
Kansas City VA Medical Center, Kansas City, MO
Kansas City, United States
Manhattan Campus of the VA NY Harbor Healthcare System, New York, NY
New York, United States
James J. Peters VA Medical Center, Bronx, NY
The Bronx, United States
Durham VA Medical Center, Durham, NC
Durham, United States
VA Portland Health Care System, Portland, OR
Portland, United States
Philadelphia MultiService Center, Philadelphia, PA
Philadelphia, United States
VA Puget Sound Health Care System Seattle Division, Seattle, WA
Seattle, United States
William S. Middleton Memorial Veterans Hospital, Madison, WI
Madison, United States
Trial contact
Robert B Montgomery, MD
Makayla L DeJong, BA
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/18/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.